赵继京+马国峰

[摘要] 目的 綜合分析联合用药治疗哮喘-慢性阻塞性肺疾病（COPD）重叠综合征患者的临床疗效。 方法 选取2011年3月～2016年3月本院收治的160例哮喘-慢性阻塞性肺疾病重叠综合征患者，按照入院顺序随机分为实验组与对照组，每组均为80例。对照组应用常规药物治疗方法，实验组在对照组基础上应用痰热清注射液联合氨溴索治疗方法。采用SPSS20.0统计学软件分析两组患者治疗前后血清炎性因子（肿瘤坏死因子α、白细胞介素-10、淋巴细胞分数）水平和治疗总有效率。 结果 （1）治疗前，两组患者的肿瘤坏死因子α、白细胞介素-10、淋巴细胞分数比较无统计学意义（P>0.05）；治疗后，实验组患者的肿瘤坏死因子α、白细胞介素-10、淋巴细胞分数显著优于对照组患者（P<0.05）；（2）实验组患者显效20例、好转58例、无效2例，治疗总有效率为97.50%（78/80），对照组患者显效11例、好转45例、无效24例，治疗总有效率为70.00%（56/80），实验组患者治疗总有效率显著高于对照组患者（P<0.05）；（3）两组患者均未出现严重不良反应。 结论 联合用药治疗哮喘-慢性阻塞性肺疾病重叠综合征患者具有显著调节作用和较高的安全性，能够进一步提高患者的临床治疗总有效率。

[关键词] 哮喘-COPD重叠综合征；联合用药；总有效率

[中图分类号] R563.9；R562.25 [文献标识码] B [文章编号] 1673-9701（2017）25-0045-03

Clinical efficacy of Tanreqing injection combined with ambroxol in the treatment of asthma-COPD overlap syndrome

ZHAO Jijing1 MA Guofeng2

1.Department of Respiratory Medicine， Jiande First Peoples Hospital in Zhejiang Province， Jiande 311600， China； 2.Department of Respiratory Medicine， Sir Run Run Shaw Hospital， Zhejiang University School of Medicine， Hangzhou 310016， China

[Abstract] Objective To comprehensively analyze the clinical efficacy of combined therapy in the treatment of asthma-chronic obstructive pulmonary disease（COPD） overlap syndrome. Methods A total of 160 patients with asthma-chronic obstructive pulmonary disease（COPD） overlap disease who were admitted to our hospital from March 2011 to March 2016 were selected. According to the order of admission， the patients were randomly divided into experimental group and control group， with 80 patients in each group. The control group was given conventional drug therapy， and the experimental group was given Tanreqing injection combined with ambroxol on the basis of the control group. SPSS20.0 statistical software was used to analyze the levels of serum inflammatory factors（tumor necrosis factor α， interleukin-10， lymphocyte score） before and after the treatment and the total effective rate in both groups. Results （1）There were no statistically significant differences in tumor necrosis factor α， interleukin-10 and lymphocyte scores between the two groups before treatment（P>0.05）； after treatment， the levels of tumor necrosis factor α， interleukin-10 and lymphocyte score in the experimental group were significantly better than those in the control group（P<0.05）； （2）There were 20 cases of significantly effective in the experimental group， 58 cases of improved， and 2 cases of invalid. The total effective rate was 97.50%（78/80）. There were 11 cases of significantly effective in the control group， 45 cases of improved， and 24 cases of invalid. The total effective rate was 70.00%（56/80）. The total effective rate of the patients in the experimental group was significantly higher than that in the control group（P<0.05）； （3）There were no severe adverse reactions between the two groups of patients. Conclusion Combined therapy has a significant regulatory effect and a relatively high safety in the patients with asthma-chronic obstructive pulmonary disease overlap syndrome， which can further improve the total effective rate of clinical treatment in patients.endprint

[Key words] Asthma-COPD overlap syndrome； Combined drug use； Total effective rate of clinical treatment

哮喘和慢性阻塞性肺疾病是两种不同的疾病，也具有不同的临床表现，临床难以将哮喘和慢性阻塞性肺疾病加以明确区分，尤其是当哮喘患者在病情加重时会出现类似慢性阻塞性肺疾病症状[1-2]。对于具有吸烟史的慢性阻塞性肺疾病患者而言，出现哮喘临床特征时，会同时具备哮喘和慢性阻塞性肺疾病特征的疾病状态，将其定义为哮喘-慢性阻塞性肺疾病重叠综合征[3-5]。慢性阻塞性肺疾病经由淋巴细胞、巨噬细胞和慢性炎性疾病等以气流受限为主要特征的疾病基础上恶化而成，一般可以进行预防。笔者将根据相关工作经验，综合分析哮喘-慢性阻塞性肺疾病重叠综合征相关性疾病联合用药疗效，为治疗哮喘-慢性阻塞性肺疾病重叠综合征患者提供科学的数据参考，现报道如下。